Disposition Kinetics of Moclobemide, a New Mao‐A Inhibitor, in Subjects with Impaired Renal Function
- 1 March 1990
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 30 (3) , 272-284
- https://doi.org/10.1002/j.1552-4604.1990.tb03472.x
Abstract
A single intravenous and oral dose of moclobemide (Ro 11–1163) was administered to 13 subjects with varying degrees of renal impairment (creatinine clearances ranging from 0 to 40 mL/min). The resulting disposition and absorption parameters of moclobemide were more variable than but, with the exception of mean absorption time, were not significantly different from values obtained in another study conducted in 12 normal healthy subjects. There were no relationships between any of the disposition parameters and renal function as measured by creatinine clearance. The disposition of two metabolites of moclobemide were partially characterized from plasma data. One of these (Ro 12–8095) appears to be formation rate-limited and, from available data, behaves in a manner similar to what has been observed in normals. The other metabolite (Ro 12–5637) has a long apparent disposition half-life and is present in greater concentrations in the renally impaired compared to the normal subjects. The latter observation may reflect reduced elimination clearance in the renally impaired subjects. Based upon the results of this study there does not appear to be any need to alter the normal dosing regimen of moclobemide in subjects with renal impairment in order to achieve drug concentrations similar to those in healthy subjects.This publication has 13 references indexed in Scilit:
- Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: Single and multiple dosing in normal subjectsClinical Pharmacology & Therapeutics, 1987
- Determination of the new monoamine oxidase inhibitor moclobemide and three of its metabolites in biological fluids by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1987
- A Simple Method for Obtaining the Mean Residence Time of Metabolites in the BodyJournal of Pharmaceutical Sciences, 1986
- Moclobemide, a new reversible MAO inhibitor ? interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patientsPsychopharmacology, 1986
- Pharmacokinetics of tenoxicam in patients with impaired renal functionEuropean Journal of Clinical Pharmacology, 1986
- Estimation of Variance for Harmonic Mean Half-LivesJournal of Pharmaceutical Sciences, 1985
- A controlled study of a specific MAO a reversible inhibitor (R011-1163) and amitriptyline in depressive illnessJournal of Affective Disorders, 1985
- Moclobemide and clomipramine in the treatment of depression.Acta Psychiatrica Scandinavica, 1984
- A Placebo-controlled Study of the Antidepressant Activity of Moclobemide,A New MAO-A InhibitorPharmacopsychiatry, 1984